- Open
- 6.60
- High
- 6.55
- Low
- 6.13
- Close
- 6.22
- Change
- -0.60 (-9.09%)
- Volume
- 280,003
| 9 Oct 2026 | 16:15:00 | EXERCISE OF WARRANTS AND ISSUE OF EQUITY |
| 6 Oct 2026 | 16:02:04 | ISSUE OF EQUITY AND GRANT OF OPTIONS |
| 1 Oct 2026 | 07:00:04 | Investor Presentation via Engage Investor |
| 1 Oct 2026 | 07:00:04 | Board Change & Appointment of New CFO |
| 30 Sept 2026 | 07:00:08 | Participation in The Small Cap Showcase |
| 25 Jun 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 20 May 2025 | 2024 Annual Report | |
| 1 May 2024 | 2023 ANNUAL REPORT AND FINANCIAL STATEMENTS |
Coiled Therapeutics PLC is a biotechnology company focused on developing AO-252, a small molecule inhibitor targeting the TACC3 protein, which is over-expressed in various cancer cells. The company holds an exclusive worldwide license for AO-252, which has demonstrated preclinical efficacy in treating ovarian, triple negative breast, endometrial, gastric, and prostate cancers, as well as brain metastases. Coiled Therapeutics is engaged in clinical trials for AO-252 in advanced solid tumors, aiming to address significant unmet medical needs in oncology.
| 9 Oct 2026 | 16:15:00 | EXERCISE OF WARRANTS AND ISSUE OF EQUITY |
| 6 Oct 2026 | 16:02:04 | ISSUE OF EQUITY AND GRANT OF OPTIONS |
| 1 Oct 2026 | 07:00:04 | Investor Presentation via Engage Investor |
| 1 Oct 2026 | 07:00:04 | Board Change & Appointment of New CFO |
| 30 Sept 2026 | 07:00:08 | Participation in The Small Cap Showcase |
| 25 Jun 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 20 May 2025 | 2024 Annual Report | |
| 1 May 2024 | 2023 ANNUAL REPORT AND FINANCIAL STATEMENTS |
Coiled Therapeutics PLC is a biotechnology company focused on developing AO-252, a small molecule inhibitor targeting the TACC3 protein, which is over-expressed in various cancer cells. The company holds an exclusive worldwide license for AO-252, which has demonstrated preclinical efficacy in treating ovarian, triple negative breast, endometrial, gastric, and prostate cancers, as well as brain metastases. Coiled Therapeutics is engaged in clinical trials for AO-252 in advanced solid tumors, aiming to address significant unmet medical needs in oncology.
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £298m | -0.1% | |
| £28m | -0.7% | |
COILCoiled Therapeutics PLC | £27m | — |
| £11m | +0.0% | |
| £3m | -0.5% | |
| £730k | -0.2% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £298m | -0.1% | |
| £28m | -0.7% | |
COILCoiled Therapeutics PLC | £27m | — |
| £11m | +0.0% | |
| £3m | -0.5% | |
| £730k | -0.2% |
